| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Letter; Research Support, Non-U.S. Gov't
- Language: English
- [Br J Haematol] 2022 Nov; Vol. 199 (3), pp. 458-462. <i>Date of Electronic Publication: </i>2022 Aug 26.
- MeSH Terms: Lymphoma, Follicular* ; Humans ; Survival Analysis ; Disease Progression
- References: Mozas P, Nadeu F, Rivas-Delgado A, Rivero A, Garrote M, Balagué O, et al. Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer J. 2020;10(3):31. https://doi.org/10.1038/s41408-020-0299-0. ; Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981-7. ; Mounier M, Bossard N, Belot A, Remontet L, Iwaz J, Dandoit M, et al. Trends in excess mortality in follicular lymphoma at a population level. Eur J Haematol. 2015;94(2):120-9. ; Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia. 2015;29(3):668-76. ; Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-22. ; Morrison VA, Shou Y, Bell JA, Hamilton L, Ogbonnaya A, Raju A, et al. Treatment patterns and survival outcomes in patients with follicular lymphoma: a 2007 to 2015 humedica database study. Clin Lymphoma, Myeloma Leuk. 2019;19(4):e172-83. https://doi.org/10.1016/j.clml.2018.12.017. ; Provencio M, Royuela A, Torrente M, Pollán M, Gómez-Codina J, Sabín P, et al. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group. Cancer. 2017;123(19):3709-16. ; Seymour JF, Marcus R, Davies A, Evans EG, Grigg A, Haynes A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202-8. ; Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Muntañola A, Nadeu F, et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019;185(3):480-91. ; Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096-101. ; Remontet L, Uhry Z, Bossard N, Iwaz J, Belot A, Danieli C, et al. Flexible and structured survival model for a simultaneous estimation of non-linear and non-proportional effects and complex interactions between continuous variables: performance of this multidimensional penalized spline approach in net survival trend ana. Stat Methods Med Res. 2019;28(8):2368-84. ; Max Planck Institute for Demographic Research M. Human Life Table Database (www.lifetable.de). 2020. ; Rajamäki A, Hujo M, Sund R, Prusila REI, Kuusisto MEL, Kuitunen H, et al. Mortality among patients with low-grade follicular lymphoma: a binational retrospective analysis. Cancer. 2022;128(13):2474-82. https://doi.org/10.1002/cncr.34221. ; Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144-52. ; Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J Clin Oncol. 2017;35(5):552-60.
- Contributed Indexing: Keywords: POD24; cause of death; event-free survival; follicular lymphoma; mortality; progression of disease
- Entry Date(s): Date Created: 20220827 Date Completed: 20221021 Latest Revision: 20221102
- Update Code: 20240513
|
